Search
Edetate calcium disodium anhydrous
go.drugbank.com/drugs/DB14598ApprovedInvestigational[L12774] It is on the World Health Organization Model List of Essential Medicines.[A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]
Categories: Compounds used in a research, industrial, or household settingQuinidine
go.drugbank.com/drugs/DB00908ApprovedThis alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. … A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.
Categories: Compounds used in a research, industrial, or household settingBenzphetamine
go.drugbank.com/drugs/DB00865ApprovedIllicitIt is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Synonyms: (+)-N-benzyl-N,α-dimethylphenethylamine, (S)-(+)-N-benzyl-N,α-dimethylphenethylamineTafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35677] It was FDA approved on July 20, 2018.[L3770]
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation. … [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]
Loxoprofen
go.drugbank.com/drugs/DB09212ApprovedInvestigationalA transdermal preparation was approved for use in Japan in January 2006. … It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina.
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively. … Linaclotide is a synthetic 14-amino acid cyclic peptide [A260271] and first-in-class guanylate cyclase-C (G-CC) agonist.
Etelcalcetide
go.drugbank.com/drugs/DB12865ApprovedInvestigationalEtelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. … Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigationalRemimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. … [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722]
Metyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalAn inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.